Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

story of the week

Published in Obesity, Metabolic Syndrome, and Prediabetes and

Journal Scan / Research · December 27, 2021

Higher Ultra-Processed Food Intake Increases All-Cause and CVD-Specific Mortality in Patients With CVD

European Heart Journal

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Ashish Aggarwal MD, FACC, FSCAI

European Heart Journal

Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Moli-sani Study

Eur Heart J 2021 Nov 30;[EPub Ahead of Print], M Bonaccio, S Costanzo, A Di Castelnuovo, M Persichillo, S Magnacca, A De Curtis, C Cerletti, MB Donati, G de Gaetano, L Iacoviello

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

Higher Ultra-Processed Food Intake Increases All-Cause and CVD-Specific Mortality in Patients With CVD

Additional Info

Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Moli-sani Study

Further Reading

Use of Semaglutide for the Primary Prevention of Diabetic Kidney Disease in People With Type 2 Diabetes

Gut-Derived Appetite Hormones Do Not Explain Energy Intake Differences in Humans Following Low-Carbohydrate vs Low-Fat Diets

Nutritional Considerations With Antiobesity Medications

Role of Incretin Receptor Agonists in Treatment of Obesity

Efficacy and Safety of SGLT2 Inhibitors With and Without GLP-1 Receptor Agonists

Impact of GLP-1 RAs on Cardiorenal Outcomes and Mortality in People With Type 2 Diabetes and Acute Kidney Disease

Effects of Semaglutide With and Without Concomitant SGLT2 Inhibitor Use in People With Type 2 Diabetes and Chronic Kidney Disease

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis With Liver Fibrosis

Effect of Semaglutide on Regression and Progression of Glycemia in Individuals With Overweight/Obesity but Without Diabetes

Association of Overweight or Obesity and Overweight or Obesity–Related Metabolic Dysfunction–Associated Steatotic Liver Disease in Young Adults With Coronary Artery Calcification Later in Life

Tirzepatide for the Treatment of OSA and Obesity

Recently Updated